AUAUniversity

Presented by Kelly Stratton, MD and Alicia Morgans, MD

This educational activity is supported by independent educational grants from:

AbbVie

Astellas

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc.

CME Available: https://auau.auanet.org/node/30123

Case-Based Discussion: BCR and mHSPC and M0 CRPC

Presented by Stephen Boorjian, MD and Michael Cookson, MD

This educational activity is supported by independent educational grants from:

AbbVie

Astellas

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc.

CME Available: https://auau.auanet.org/node/30122

At the conclusion of this activity, participants will be able to:

1. Identify the role of genetic testing in men with advanced, metastatic and CRPC.

2. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

3. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.

4. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

At the conclusion of this activity, participants will be able to:

1. Examine racial and geographic disparities in in prostate cancer and prostate cancer care.

2. Identify important causes for disparities as well as possible remedies to address these causes.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

At the conclusion of this activity, participants will be able to:

1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment.

2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

CME Available: https://auau.auanet.org/node/29841

At the conclusion of this activity, participants will be able to:

1. Review the evidence and outcomes on the treatment of M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced, Metastatic and CRPC guidelines.

2. Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice

This educational series is supported by independent educational grants from:

• Astellas

• AstraZeneca

• Bristol Myers Squibb

• Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

• Merck

• Pfizer, Inc

• Sanofi Genzyme

• UroGen Pharma, Inc.

CME Available: https://auau.auanet.org/node/30174

At the conclusion of this activity, participants will be able to:

1. Describe new and emerging targeted for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy.

2. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC.

3. Facilitate discussions with patients and caregivers regarding RCC treatment options.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

CME Available: https://auau.auanet.org/node/29851

Case-Based Discussion: BCR and mHSPC and M0 CRPC

Presented by Stephen Boorjian, MD and Michael Cookson, MD

This educational series is supported by independent educational grants from AbbVie, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck.

CME Available: https://auau.auanet.org/node/30122

Immune Checkpoint Inhibitors in RCC

At the conclusion of this activity, participants will be able to:

1. Discuss the current immunotherapy options available for the treatment of RCC.

2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.

3. Identify and manage immune related adverse events.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

CME Available: https://auau.auanet.org/node/29846

The Expanding Role of Immune Checkpoint Inhibitors in MIBC and NMIBC

At the conclusion of this activity, participants will be able to:

1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer.

2. Describe the mechanism of action of immunotherapy regimens.

3. Identify and manage the adverse events related to these agents.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

CME Available: https://auau.auanet.org/node/29831